We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMTFB
RNS Number : 7038D
Motif Bio PLC
28 April 2017
28 April 2017
Motif Bio plc
("Motif Bio" or the "Company")
Change of Nominated Adviser and Joint Broker
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce the appointment of Peel Hunt LLP as nominated adviser and joint corporate broker with immediate effect.
For further information please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900 Dr Christopher Golden Oliver Jackson Northland Capital Partners Limited (BROKER) +44 (0)203 861 6625 Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) Walbrook PR Ltd. (FINANCIAL +44 (0) 20 7933 8780 or PR & IR) motifbio@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893 Mike Wort Mob: +44 (0)7900 608 002 MC Services AG (EUROPEAN IR) +49 (0)89 210 2280 Raimund Gabriel
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPIPMMTMBTTBLR
(END) Dow Jones Newswires
April 28, 2017 07:00 ET (11:00 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
